Quest For Growth

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

Finquest is a leading deal origination provider that specializes in delivering personalized connections for clients seeking mergers and acquisitions (M&A) and direct investment opportunities across Europe, North America, and the Asia-Pacific region. Utilizing a unique database and advanced machine learning techniques, Finquest offers targeted and curated introductions, facilitating a more efficient deal-making process while ensuring complete confidentiality. The company's platform focuses on the middle market, connecting institutional investors with potential investment opportunities and enabling corporate buyers to identify relevant acquirers. Headquartered in Singapore, Finquest operates offices in key financial centers including New York, Dallas, London, Paris, Frankfurt, Luxembourg, Bangalore, and Hong Kong, broadening market access for its clients.

Qpinch is a company that specializes in transforming industrial waste heat into carbon-neutral steam, which can be used to generate electricity and useful process heat. By utilizing their innovative chemical heat transformer, Qpinch helps businesses reduce their energy costs while minimizing their environmental impact. The company's technology is designed to integrate with existing industrial assets, allowing clients to achieve immediate savings on their energy bills. This focus on sustainability and efficiency positions Qpinch as a valuable partner for industries that rely on process heat.

EclecticIQ is a company specializing in threat intelligence and cybersecurity solutions. It develops advanced technology for threat hunting and response, aimed at enhancing organizations' defenses against cyber adversaries. The company's platform integrates and interprets intelligence data sourced from open sources, commercial suppliers, and industry partnerships. This enables enterprises to bolster their detection, prevention, and response capabilities by embedding actionable intelligence into their cybersecurity infrastructures. Through its offerings, EclecticIQ strives to empower organizations to effectively combat evolving cyber threats.

Sensolus NV specializes in the design and development of GPS trackers for non-powered assets, providing comprehensive tracking solutions directly from the cloud. Established in 2013 and based in Ghent, Belgium, the company offers a range of low-power, context-aware sensing technologies, including its STICKNTRACK product line. Sensolus combines hardware GPS trackers with a fully integrated cloud application, enabling users to manage and monitor their assets with ease. The company serves various industries, including manufacturing, waste management, cargo transport, logistics, and automotive, focusing on delivering real-time information and maintenance-free asset tracking solutions.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

HalioDx is a company focused on designing and developing diagnostic tests in oncology that assess the immune contexture of cancers. It offers a range of immunologic scoring tests that investigate the immune response within the tumor environment. Utilizing a proprietary set of immune biomarkers and advanced image analysis technologies, HalioDx's tests accurately measure the immune reaction in and around tumors. This information helps clinicians evaluate the severity of a patient's disease and predict their response to treatment, ultimately aiding in personalized patient care.

Sensolus NV specializes in the design and development of GPS trackers for non-powered assets, providing comprehensive tracking solutions directly from the cloud. Established in 2013 and based in Ghent, Belgium, the company offers a range of low-power, context-aware sensing technologies, including its STICKNTRACK product line. Sensolus combines hardware GPS trackers with a fully integrated cloud application, enabling users to manage and monitor their assets with ease. The company serves various industries, including manufacturing, waste management, cargo transport, logistics, and automotive, focusing on delivering real-time information and maintenance-free asset tracking solutions.

Sequana Medical AG is a Swiss medical device company that specializes in developing implantable pump systems to manage fluid balance in the body. Its flagship product, the alfapump, is designed to continuously remove ascites, a condition characterized by fluid accumulation in the abdominal cavity, commonly seen in patients with advanced liver disease, certain cancers, or congestive heart failure. The alfapump is notable for being the first automated system that facilitates the natural expulsion of excess fluid through urination. In addition to treating ascites, the company's pump technology has potential applications in managing pleural effusions and fluid overload in patients with end-stage renal disease and heart failure. Founded in 2002 and headquartered in Zurich, Switzerland, Sequana Medical has expanded its reach to various markets, with a significant portion of its revenue generated in Germany.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease. Established in 2006, the company specializes in creating generic mono and combination therapies that incorporate inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. Prosonix employs proprietary ultrasonic particle engineering technologies to enhance the manufacture of inhaled medications, enabling the design of drug particles tailored for effective inhalation. The company also works on dual and triple combination therapies to provide comprehensive treatment options for respiratory conditions. As of mid-2015, Prosonix operates as a subsidiary of Circassia Limited.

Cartagenia specializes in providing software and services for clinical genetics and molecular pathology laboratories. The company offers a platform designed for the assessment and reporting of clinical genomics data derived from next-generation sequencing and microarrays. This platform facilitates the visualization, assessment, and reporting of genetic data in relation to patient information, enabling genetic labs and clinicians to conduct clinically relevant analyses efficiently. By improving the speed and quality of genetic interpretation and counseling, Cartagenia aims to enhance the overall experience for patients and caregivers.

Prosonix Ltd. is a specialty pharmaceutical company based in Oxford, United Kingdom, focused on developing and marketing inhaled medicines for the treatment of asthma and chronic obstructive pulmonary disease. Established in 2006, the company specializes in creating generic mono and combination therapies that incorporate inhaled corticosteroids, long-acting beta agonists, and long-acting muscarinic antagonists. Prosonix employs proprietary ultrasonic particle engineering technologies to enhance the manufacture of inhaled medications, enabling the design of drug particles tailored for effective inhalation. The company also works on dual and triple combination therapies to provide comprehensive treatment options for respiratory conditions. As of mid-2015, Prosonix operates as a subsidiary of Circassia Limited.

Anteryon International, established in 2006, is a Netherlands-based company specializing in the design, manufacture, and distribution of high-precision optical solutions. It offers a wide range of products, including various types of lenses, laser modules, optical mirrors, filters, and custom opto-mechatronic assemblies. Serving diverse sectors such as medical, telecom, defense, and semiconductor industries, Anteryon caters to over 100 global customers. Its unique replication and opto-mechanical assembly technology, along with deep expertise in coatings and precision glass, enables the company to deliver optical solutions from components to finished products. Anteryon operates as a subsidiary of China Wafer Level CSP Co., Ltd.

Active Circle develops and markets software solutions aimed at organizations that handle large volumes of digital content. Their innovative software is designed for the storage, preservation, and management of various types of files, including video content, images, and scientific and technical data. By offering tools that enable clients to effectively control the lifecycle of their data, Active Circle helps organizations reduce storage costs and improve efficiency in managing their digital assets.

CoreOptics specializes in providing advanced solutions for high-speed optical networking applications within the telecommunications and information technology sectors. The company is recognized for its 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, which are essential for Metro, Regional, and Long Haul optical and data networks. CoreOptics advocates for open optical communication systems that can efficiently transmit data across various rates and fiber types. Its innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is notable for enabling Tier 1 systems vendors and carriers to enhance network performance without overhauling existing fiber infrastructure. By eliminating the need for Optical Compensators and Second Stage Amplifiers, CoreOptics' products can significantly lower first-in deployment costs for customers, achieving reductions of up to 30%.

iNEWiT is an engineering company based in Mechelen, Belgium, founded in 2005. The company specializes in identifying, designing, and creating applications and devices for the mobile market. It develops mobile video communication applications and offers a range of wireless communication technologies, including GPRS/EDGE, 3G, HSDPA/HSUPA, WiFi, WiMAX, and satellite networks. iNEWiT's products utilize patent-pending technology to transmit data, video, and sound across various wireless and wired environments and platforms. Additionally, the company provides plug-and-play products tailored for the business-to-consumer markets.

Certess is an electronic design automation (EDA) company that specializes in functional qualification products aimed at businesses developing and integrating complex design blocks or intellectual property (IP). The company's software addresses the challenges faced by advanced functional verification teams, who often struggle to achieve true verification quality despite using various techniques. Certess provides tools that enable design and verification engineers to objectively evaluate and enhance the completeness of their verification environments, which helps reduce functional logic errors—key contributors to chip respins. By streamlining the integration process of System-on-Chip (SoC) designs, Certess ensures higher quality outcomes. Founded in 2005 and based in Campbell, California, Certess was acquired by SpringSoft, LLC in March 2009.

TcLand Expression is a fully integrated company displaying high expertise in all stages of biomarker development: R&D, bioinformatics & biostatistics, clinical & regulatory , market access and production. TcLand Expression is a pioneer and European leader in personalized medicine in immunology (transplantation and auto-immune disorders) with a rich pipeline of biomarkers in development.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Kiadis Pharma N.V. is a clinical-stage biopharmaceutical company based in Amsterdam, the Netherlands, specializing in the development of cell-based immunotherapy products for blood cancers and inherited blood disorders. The company is currently advancing its product pipeline, which includes K-NK002, an adjunctive immunotherapeutic in Phase II trials for blood cancer patients undergoing haploidentical hematopoietic stem cell transplants, and K-NK003, which is in Phase I/II trials for patients with acute myeloid leukemia who are relapsed or refractory. Additionally, Kiadis Pharma is developing K-NK00X, a preclinical NK-cell therapy candidate aimed at treating various solid tumors. The company is engaged in collaborative efforts with multiple institutions to explore innovative treatments, including a combination of a monoclonal antibody and natural killer cells for COVID-19. Established in 1997, Kiadis Pharma addresses critical unmet medical needs in oncology through its innovative therapeutic approaches.

MAPPER Lithography B.V. specializes in developing maskless lithography infrastructure for the semiconductor industry. Founded in 2000 and headquartered in Delft, the Netherlands, the company designs and manufactures tools that utilize multiple electron-beam technology for semiconductor production. This innovative approach enables the fabrication of chips without the need for traditional masks, streamlining the manufacturing process. MAPPER Lithography also operates a manufacturing facility in Moscow, Russia, further supporting its capabilities in the semiconductor sector.

Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. The company addresses a range of conditions, including severe chronic constipation, ascites, and pediatric reflux, as well as severe GI motility disorders like refractory gastro-oesophageal reflux disease. Its lead product, Resolor, is specifically designed for the symptomatic treatment of chronic constipation in women, with ongoing research for its efficacy in males and children, as well as in cases of opioid-induced constipation and post-operative ileus. Movetis is also developing M0002, currently in Phase II trials for treating ascites, and M0003, which is set to enter Phase II development for symptomatic relief of heartburn and regurgitation in patients unresponsive to proton pump inhibitors. Additionally, the company has two prioritized compounds from its preclinical portfolio and maintains partnerships with universities in Ghent, Leuven, and Rotterdam. Founded in 2006, Movetis is based in Turnhout, Belgium.

Plastic Logic Ltd specializes in the development and manufacturing of plastic electronics, particularly flexible displays. The company produces both color and monochrome electrophoretic displays, which are utilized in a variety of applications including smartphones, e-readers, tablets, signage, wristwatches, and automotive displays. With a focus on lightweight, shatterproof, and energy-efficient technology, Plastic Logic's products offer significant advantages over traditional screens. The company's manufacturing capabilities are centered in Dresden, Germany, where it operates a pioneering facility dedicated to organic electronics. It serves a diverse clientele, including OEMs, system integrators, and device manufacturers in multiple countries, including the United Kingdom, Germany, and Russia. Additionally, Plastic Logic collaborates with third-party companies through an open pilot line, providing expertise in the industrialization of flexible electronics. Founded in 2000 and based in Cambridge, Plastic Logic continues to innovate in the field of flexible display technology.

CoreOptics specializes in providing advanced solutions for high-speed optical networking applications within the telecommunications and information technology sectors. The company is recognized for its 10G and 40G Distortion Tolerant Transponder Modules and integrated circuit solutions, which are essential for Metro, Regional, and Long Haul optical and data networks. CoreOptics advocates for open optical communication systems that can efficiently transmit data across various rates and fiber types. Its innovative maximum likelihood sequence estimation (MLSE)-based equalization technology is notable for enabling Tier 1 systems vendors and carriers to enhance network performance without overhauling existing fiber infrastructure. By eliminating the need for Optical Compensators and Second Stage Amplifiers, CoreOptics' products can significantly lower first-in deployment costs for customers, achieving reductions of up to 30%.

Clear2Pay is a payments technology company that specializes in delivering innovative solutions for electronic payments processing. The company's Open Payment Framework (OPF) provides financial institutions with the ability to enhance the efficiency of their internal payment systems while offering clients improved services characterized by speed and comprehensive payment information. Clear2Pay's OPF operates within a Service-Oriented Architecture, enabling banks to process payments through a centralized engine that utilizes a library of reusable business services across various payment types. This approach allows financial institutions to integrate new service models with existing infrastructures, ensuring the protection of previous investments while transitioning to a more modern and efficient payment environment. Additionally, Clear2Pay provides a Software Development Kit and a Bank Payment Hub, which offer tools for implementing payment solutions and managing customer interactions, order execution, and dispute processing.

Gemidis is a spin-off company from Ghent University (Belgium) and IMEC (Belgium) and was officially founded in August 2004. Gemidis develops, produces and sells LCOS imagers and driver electronics for both consumer and professional markets.

Welcome Real Time S.A. is a company that specializes in electronic payment software and services, primarily for financial institutions, payment networks, and retailers. Established in 1996 and headquartered in Aix-en-Provence, France, it offers a variety of solutions including credit and debit card acceptance, and integrated value-added services. Key products include XLS Server, which enhances EMV capabilities for payment processing systems; XLS POS, a toolkit for developing payment applications; and XLS Card, which supports card personalization and issuance. Additionally, Welcome Real Time provides CardCare for cardholder services and MerchantCare for merchant activity reporting. With research and development facilities in multiple global locations, the company focuses on creating point-of-sale customer loyalty programs and smart payment device software, along with offering maintenance and marketing consulting services.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other proliferative diseases. The company is advancing several oncology programs, including CYC065, a cyclin-dependent kinase (CDK) inhibitor currently in Phase I trials for solid tumors and in combination with venetoclax for chronic lymphocytic leukemia. CYC140, a polo-like kinase inhibitor, is also in Phase I trials for advanced leukemias. Additionally, sapacitabine, an oral nucleoside analogue prodrug, is being evaluated in a Phase 1/2 combination study with seliciclib, another CDK inhibitor, for patients with BRCA mutations. Cyclacel's pipeline includes collaborations with notable institutions, such as the University of Texas MD Anderson Cancer Center, to assess the safety and efficacy of its treatments in hematological malignancies. The company was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

Oxagen Limited is a biopharmaceutical company focused on developing and commercializing anti-inflammatory medications for asthma and other chronic allergic conditions. The company specializes in small molecule drugs, including OC000459, an oral CRTH2 antagonist aimed at treating eosinophilic asthma and allergic rhinoconjunctivitis. Oxagen's drug development targets the CRTH2 receptor, which plays a critical role in the initiation and maintenance of allergic responses. In addition to asthma, their pipeline includes treatments for autoimmune diseases, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Founded in 1996 and based in London, Oxagen serves customers in the United Kingdom, Russia, and other countries in the Commonwealth of Independent States.